| Literature DB >> 29121956 |
Marco M Ochs1, Thomas Fritz2, Nisha Arenja2, Johannes Riffel2, Florian Andre2, Derliz Mereles2, Fabian Aus dem Siepen2, Ute Hegenbart3, Stefan Schönland3, Hugo A Katus2, Matthias G W Friedrich2, Sebastian J Buss2.
Abstract
BACKGROUND: To compare the prognostic value of cardiac valve plane displacement (CVPD) on various locations in cardiac light chain (AL) amyloidosis.Entities:
Keywords: AAPSE; AL amyloidosis; Anterior aortic plane systolic excursion; Cardiac valve plane excursion; MAPSE; Risk assessment; TAPSE
Mesh:
Year: 2017 PMID: 29121956 PMCID: PMC5680757 DOI: 10.1186/s12968-017-0402-2
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1a Patient selection flow chart. From 2005 to 2014 a total of 1.181 AL patients visited our institution. Patients had to be excluded for negative or absent cardiac biopsy (Bx), absent CMR examination, or CMR performed after induction of chemotherapy (CHT). The final study cohort consists of 68 AL patients. b Late gadolinium enhancement (LGE) quantification by semiautomatic 5 SD-threshold selection. Contours for endo- (red) and epicardial borders (green) as well as for unenhanced reference myocardium (blue) were drawn manually. Signal intensities above 5-fold standard deviation of the reference myocardium were accounted to the LGE volume in relation to unenhanced myocardium (relative LGE, orange)
Baseline Characteristics. Patients with primary combined endpoint versus transplant-free survivors (n = 68)
| Parameter | Transplant-free Survivors | Heart transplantation or death | p |
|---|---|---|---|
| Age (yrs) | 57 ± 8 | 59 ± 11 |
|
| Male (n)a | 13 (54%) | 27 (61%) |
|
| BMI (kg/m2) | 25 (23-27) | 25 (23-27) |
|
| Heart rate (bpm) | 78 ± 13 | 80 ± 14 |
|
| NYHA class | 2 (2-3) | 3 (2-3) |
|
| Karnofsky Index | 85 ± 6 | 76 ± 10 |
|
|
| |||
| MDRD (mL/min/1.73m2) | 81 ± 17 | 83 ± 14 |
|
| NT-proBNP (pg/mL) | 1177 (528-3249) | 3243 (1157-7505) |
|
| cTNT ULN (n)a | 8 (38%) | 18 (41%) |
|
| FLC difference (mg/dL) | 1,1130 (435-5435) | 3351 (975-8971) |
|
|
| |||
| AAPSE (mm) | 8.8 (6.9-10.4) | 6.1 (4.6-9.4) |
|
| MAPSE anterior (mm) | 8.1 (5.3-10.0) | 6.2 (4.1-8.6) |
|
| MAPSE anterolateral (mm) | 10.5 (8.1-13.4) | 7.3 (5.4-11.7) |
|
| MAPSE inferolateral (mm) | 9.3 (6.3-12.1) | 7.6 (5.2-12.2) |
|
| MAPSE inferior (mm) | 9.2 (7.4-11.1) | 8.0 (5.0-11.7) |
|
| MAPSE inferoseptal (mm) | 7.6 (6.1-10.4) | 7.1 (4.5-10.8) |
|
| TAPSE (mm) | 18.0 (10.0-22.4) | 14.1 (9.0-19.7) |
|
| GLS (%) | −14.8 ± 5.1 | −13.2 ± 5.2 |
|
| LSbasal (%) | −12.3 ± 6.1 | −11.4 ± 8.5 |
|
| LSmid (%) | −16.4 ± 5.2 | −14.7 ± 5.5 |
|
| LSapical (%) | −17.6 ± 5.9 | −16.2 ± 6.6 |
|
| Ejection Fraction (%) | 62 ± 10 | 55 ± 13 |
|
| Septal wall (mm) | 14 ± 5 | 13 ± 3 |
|
| Lateral wall (mm) | 10 ± 4 | 10 ± 4 |
|
| Relative LV Mass (g/m2) | 75 ± 21 | 73 ± 35 |
|
| LA (mm) | 39 ± 7 | 42 ± 7 |
|
| Relative LGE (%) | 16.5 (10.0-35.7) | 25.0 (18.1-30.4) |
|
| Qualitative LGE (n) | 2 (2-3) | 2 (2-3) |
|
Normal distributed variables are presented as mean ± SD, non-parametric distributions are shown as Median (1st quartile-3rd quartile). adichotomous variable
BMI body mass index, MDRD glomerular filtration rate calculated with the formula of “Modification of Diet in Renal Disease”, NT-proBNP N-terminal prohormone of brain natriuretic peptide, cTNT ULN cardiac troponin T upper limit of normal, FLC free light chain difference, AAPSE anterior aortic plane systolic excursion, MAPSE mitral annular plane systolic excursion, TAPSE tricuspid annular plane systolic excursion, GLS global longitudinal strain, LS mean longitudinal strain of basal segments 1-6, LS mean longitudinal strain of midventricular segments 7-12, LS mean longitudinal strain of apical segments 13-16, LA left atrium, relative LGE proportion of late gadolinium enhancement quantified by 5SD method, qualitative LGE Late Gadolinium Enhancement graduated in (1) none, (2) subendocardial or (3) transmural involvement
Fig. 2Distribution of the prognostic value for cardiac valve plane displacement on varying locations. Chi-square (X2) resulted from univariate regression analyses. To relate the prognostic value of cardiac valve plane motion with established predictors in AL amyloidosis relative LLGE and global longitudinal strain (GLS) are presented
Univariate Cox-regression for overall survival or heart transplantation (n = 68)
| Variable | X2 | HR | 95% CI | p |
|---|---|---|---|---|
| NYHA class |
| 1.75 | 1.15 to 2.68 |
|
| Karnofsky Index |
| 0.91 | 0.88 to 0.95 |
|
|
| ||||
| AAPSE (mm) |
| 0.10 | 0.03 to 0.34 |
|
| MAPSE anterior (mm) |
| 0.19 | 0.06 to 0.60 |
|
| MAPSE anterolateral (mm) |
| 0.23 | 0.10 to 0.56 |
|
| MAPSE inferolateral (mm) |
| 0.36 | 0.16 to 0.83 |
|
| MAPSE inferior (mm) |
| 0.26 | 0.10 to 0.63 |
|
| MAPSE inferoseptal (mm) |
| 0.26 | 0.10 to 0.68 |
|
| TAPSE (mm) |
| 0.94 | 0.90 to 0.99 |
|
| GLS (%) |
| 1.12 | 1.05 to 1.19 |
|
| LSbasal (%) |
| 1.08 | 1.02 to 1.13 |
|
| LSmid (%) |
| 1.13 | 1.06 to 1.21 |
|
| LSapical (%) |
| 1.07 | 1.02 to 1.12 |
|
| Ejection Fraction (%) |
| 0.95 | 0.93 to 0.98 |
|
| Septal wall (mm) |
| 1.03 | 0.96 to 1.11 |
|
| Relative LV Mass (g/m2) |
| 1.01 | 0.99 to 1.02 |
|
| LA dilation a |
| 1.05 | 0.55 to 1.97 |
|
| Relative LGE (%) |
| 1.02 | 1.00 to 1.04 |
|
| Qualitative LGE (n) |
| 1.50 | 1.09 to 2.06 |
|
|
| ||||
| cTNT ULN |
| 1.94 | 1.09 to 3.45 |
|
| log NT-proBNP (pg/mL) |
| 1.52 | 1.20 to 1.94 |
|
| MDRD (mL/min/1.73m2) |
| 1.00 | 0.99 to 1.01 |
|
| log FLC difference (mg/dL) |
| 1.71 | 1.10 to 2.65 |
|
X chi square, HR hazard ratio, CI confidence interval, adichotomous variable
AAPSE anterior aortic plane systolic excursion, MAPSE mitral annular plane systolic excursion, TAPSE tricuspid annular plane systolic excursion, GLS global longitudinal strain, LS mean longitudinal strain of basal segments 1-6, LS mean longitudinal strain of midventricular segments 7-12, LS mean longitudinal strain of apical segments 13-16, LA left atrium, relative LGE proportion of late gadolinium enhancement quantified by 5SD method, qualitative LGE late gadolinium enhancement graduated in (1) none, (2) subendocardial or (3) transmural involvement, cTNT ULN cardiac troponin T upper limit of normal, NT-proBNP N-terminal prohormone of brain natriuretic peptide, MDRD glomerular filtration rate calculated with the formula of “Modification of Diet in Renal Disease”, FLC free light chain difference
Fig. 3Kaplan-Meier survival curve demonstrates the discriminative prognostic value of AAPSE in cardiac biopsy proven AL amyloidosis. Cut-off (AAPSE ≤7.6 mm) was calculated by ROC analyses (AUC =0.80; CI: 0.68 to 0.89; p < 0.0001) and Youden’s-J statistic to predict all-cause death or heart transplantation within 6 months from index examination (n = 68)
Fig. 4Incremental prognostic power of AAPSE. Sequential Cox-regression analysis was performed to evaluate the incremental predictive power of AAPSE for transplant-free survival in an (a) imaging (LGE and GLS; χ2 = 10.2) and a (b) clinical prediction model (NT-proBNP and Karnofsky Index; χ2 = 15.4). AAPSE significantly improved the predictive power of both models (imaging: AAPSE ∆χ2 = 5.8, p = 0.02; clinical: AAPSE ∆χ2 = 6.2, p = 0.01)